Respironics ( RESP - NASDAQ ) has just reported the last Q results . Part of RESPIRONICS biz is actually the second leg in the DUOPOLY of RMD/RESP in the APNEA sleep disorder market . Key drivers for the Company's domestic revenue performance include a year-over-year increase of 15 percent in domestic sleep therapy products. Let's hope RMD did the same . First call consensus expected increase for RMD is 12% in EPS growth .It is expected to report EPS USc 28 for the Q and USD 1.06 for the FY , Duff
RMD - A possible profit clue
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$27.55 |
Change
-0.360(1.29%) |
Mkt cap ! $43.78B | |||
| Open | High | Low | Value | Volume |
| $27.48 | $27.57 | $27.37 | $37.40M | 1.357M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 226 | $27.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $27.56 | 215 | 3 |
View Market Depth
| Last trade - 11.10am 19/05/2022 (20 minute delay) ? |
 (live)
|
|||||
|
Last
$27.62 |
Change
-0.360 ( 0.90 %) |
||||
| Open | High | Low | Volume | ||
| $27.43 | $27.63 | $27.37 | 24316 | ||
| Last updated 11.28am 19/05/2022 (live) ? | |||||
| RMD (ASX) Chart |